What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy

Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg, Rudolph M. Navari

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Clinician adherence to antiemetic guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) caused by highly emetogenic chemotherapy (HEC) remains poorly characterized. The primary aim of this study was to evaluate individual clinician adherence to HEC antiemetic guidelines. Patients and Methods: A retrospective analysis of patients receiving HEC was conducted using the IBM Watson Explorys Electronic Health Record Database (2012–2018). HEC antiemetic guideline adherence was defined as prescription of triple prophylaxis (neurokinin-1 receptor antagonist [NK1 RA], serotonin type-3 receptor antagonist, dexamethasone) at initiation of cisplatin or anthracycline 1 cyclophosphamide (AC). Clinicians who prescribed $5 HEC courses were included and individual guideline adherence was assessed, noting the number of prescribing clinicians with .90% adherence. Results: A total of 217 clinicians were identified who prescribed 2,543 cisplatin and 1,490 AC courses. Patients (N54,033) were primarily women (63.3%) and chemotherapy-naïve (92%) with a mean age of 58.6 years. Breast (36%) and thoracic (19%) cancers were the most common tumor types. Guideline adherence rates of .90% were achieved by 35% and 58% of clinicians using cisplatin or AC, respectively. Omission of an NK1 RA was the most common practice of nonadherence. Variation in prophylaxis guideline adherence was considerable for cisplatin (mean, 71%; SD, 29%; coefficient of variation [CV], 0.40) and AC (mean, 84%; SD, 26%; CV, 0.31). Conclusions: Findings showed substantial gaps in clinician adherence to HEC CINV guidelines, including a high variability across clinicians. Clinicians should review their individual clinical practices and ensure adherence to evidence-based CINV guidelines to optimize patient care.

Original languageEnglish (US)
Pages (from-to)676-681
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume18
Issue number6
DOIs
StatePublished - Jun 2020

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy'. Together they form a unique fingerprint.

Cite this